General Information:

Id: 2,249 (click here to show other Interactions for entry)
Diseases: Alzheimer disease - [OMIM]
Dementia
Mammalia
review
Reference: Butterfield DA et al.(2011) Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders Pharmacol. Res. 64: 180-186 [PMID: 21536132]

Interaction Information:

Comment Statins showed positive effects against Alzheimer-relevant Abeta-induced oxidative stress in mice models of AD as well as a reduction in CSF tau protein phosphorylation in humans.
Formal Description
Interaction-ID: 19213

drug/chemical compound

Statin

affects_activity of

in mouse models of AD Alzheimer-relevant and Abeta-induced
Comment Statins showed positive effects against Alzheimer-relevant Abeta-induced oxidative stress in mice models of AD as well as a reduction in CSF tau protein phosphorylation in humans.
Formal Description
Interaction-ID: 19214

drug/chemical compound

Statin

decreases_phosphorylation of

gene/protein

MAPT

in CFS; of patients, Alzheimer-relevant and Abeta-induced
Comment Atorvastatin treatment was neuroprotective against cell degeneration induced by Abeta (1-40), reducing inflammatory and oxidative responses and increasing the expression of glutamatergic transporters.
Formal Description
Interaction-ID: 19227

drug/chemical compound

Atorvastatin

decreases_activity of

phenotype

neurodegeneration

neuroprotection against cell degeneration induced by Abeta (1-40)
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin treatment was neuroprotective against cell degeneration induced by Abeta (1-40), reducing inflammatory and oxidative responses and increasing the expression of glutamatergic transporters.
Formal Description
Interaction-ID: 19228

drug/chemical compound

Atorvastatin

decreases_activity of

Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin treatment was neuroprotective against cell degeneration induced by Abeta (1-40), reducing inflammatory and oxidative responses and increasing the expression of glutamatergic transporters.
Formal Description
Interaction-ID: 19229

drug/chemical compound

Atorvastatin

decreases_activity of

Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin treatment was neuroprotective against cell degeneration induced by Abeta (1-40), reducing inflammatory and oxidative responses and increasing the expression of glutamatergic transporters.
Formal Description
Interaction-ID: 19230

drug/chemical compound

Atorvastatin

increases_expression of

gene/protein

Glutamatergic transporter

Drugbank entries Show/Hide entries for Atorvastatin
Comment Long-term atorvastatin did not affect Abeta levels, despite a significant reduction in beta-secretase 1 (BACE1) protein levels and activity in the brain of aged beagles.
Formal Description
Interaction-ID: 19233

drug/chemical compound

Atorvastatin

NOT affects_quantity of

gene/protein

Amyloid beta peptide

Drugbank entries Show/Hide entries for Atorvastatin
Comment Long-term atorvastatin did not affect Abeta levels, despite a significant reduction in beta-secretase 1 (BACE1) protein levels.
Formal Description
Interaction-ID: 19236

drug/chemical compound

Atorvastatin

decreases_quantity of

gene/protein

BACE1

Drugbank entries Show/Hide entries for Atorvastatin or BACE1
Comment Long-term atorvastatin significantly reduced lipoperoxidation, protein oxidation and nitration, and increased GSH levels in parietal cortex of the same animals.
Formal Description
Interaction-ID: 19237

drug/chemical compound

Atorvastatin

decreases_activity of

process

lipid peroxidation

Drugbank entries Show/Hide entries for Atorvastatin
Comment Long-term atorvastatin significantly reduced lipoperoxidation, protein oxidation and nitration, and increased GSH levels in parietal cortex of the same animals.
Formal Description
Interaction-ID: 19252

drug/chemical compound

Atorvastatin

decreases_activity of

Drugbank entries Show/Hide entries for Atorvastatin
Comment Long-term atorvastatin significantly reduced lipoperoxidation, protein oxidation and nitration, and increased GSH levels in parietal cortex of the same animals.
Formal Description
Interaction-ID: 19253

drug/chemical compound

Atorvastatin

decreases_activity of

Drugbank entries Show/Hide entries for Atorvastatin
Comment Long-term atorvastatin significantly reduced lipoperoxidation, protein oxidation and nitration, and increased GSH levels in parietal cortex of the same animals.
Formal Description
Interaction-ID: 19254

drug/chemical compound

Atorvastatin

increases_quantity of

drug/chemical compound

Glutathione

cholesterol- and Abeta-independent and specific for brain
Drugbank entries Show/Hide entries for Atorvastatin or Glutathione
Comment Side effects of long-term statin treatment atorvastatin with include a decrease in CoQ10 levels resulting in energy metabolism impairment in heart, skeletal muscle, and liver.
Formal Description
Interaction-ID: 19256

drug/chemical compound

Atorvastatin

decreases_quantity of

drug/chemical compound

Ubichinon-10

(side effects of long-term statin treatment)
Drugbank entries Show/Hide entries for Atorvastatin
Comment Side effects of long-term statin treatment atorvastatin with include a decrease in CoQ10 levels resulting in energy metabolism impairment in heart, skeletal muscle, and liver.
Formal Description
Interaction-ID: 19259

drug/chemical compound

Atorvastatin

increases_activity of

in heart, skeletal muscle, and liver; (as side effect of long-term statin treatment)
Drugbank entries Show/Hide entries for Atorvastatin
Comment Early clinical data based on cohort and case-control studies, demonstrated that statins reduced the risk to develop dementia, including Alzheimer disease (AD), and this protective effect was maintained over a 6 year follow-up period.
Formal Description
Interaction-ID: 19266

drug/chemical compound

Statin

decreases_activity of

Comment Early clinical data based on cohort and case-control studies, demonstrated that statins reduced the risk to develop dementia, including Alzheimer disease (AD), and this protective effect was maintained over a 6 year follow-up period.
Formal Description
Interaction-ID: 19267

drug/chemical compound

Statin

decreases_activity of

disease

Dementia

Comment Others demonstrated that statins did not improve cognition in elderly subjects with a median age of 72 years.
Formal Description
Interaction-ID: 19268

drug/chemical compound

Statin

NOT decreases_activity of

phenotype

cognitive impairment

in elderly subjects with a median age of 72 years
Comment The PROSPER study showed that pravastatin did not improve cognitive function over a follow-up of 3 years.
Formal Description
Interaction-ID: 19269

drug/chemical compound

Pravastatin

NOT decreases_activity of

phenotype

cognitive impairment

(PROSPER study)
Drugbank entries Show/Hide entries for Pravastatin
Comment The LEADe study did not support any significant positive effect of atorvastatin on cognitive or global functions in patients receiving the statin compared to those with placebo.
Formal Description
Interaction-ID: 19270

drug/chemical compound

Atorvastatin

NOT decreases_activity of

phenotype

cognitive impairment

(LEADe study)
Drugbank entries Show/Hide entries for Atorvastatin
Comment The CLASP study was designed to evaluate the neuroprotective role of simvastatin for 18 months in mild-moderate AD patients. It failed to demonstrate a therapeutic role for simvastatin.
Formal Description
Interaction-ID: 19279

drug/chemical compound

Simvastatin

NOT decreases_activity of

(CLASP study)
Drugbank entries Show/Hide entries for Simvastatin
Comment The ADCLT trial demonstrated that atorvastatin for 1 year exhibited a significant positive effect on cognitive performance after 6 months of therapy compared with placebo.
Formal Description
Interaction-ID: 19280

drug/chemical compound

Atorvastatin

decreases_activity of

phenotype

cognitive impairment

(ADCLT trial)
Drugbank entries Show/Hide entries for Atorvastatin
Comment Subjects aged 80 or older also did not have any beneficial effects from statins.
Formal Description
Interaction-ID: 19282

process

aging

decreases_activity of

drug/chemical compound

Statin